Etiologic Causes of Invasive Fungal Sinusitis among Patients of, University Hospitals in Shiraz, Iran

Document Type : Original Article(s)

Authors

1 Resident, Department of Internal Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

2 Assistant Professor, Alborzi Clinical Microbiology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

3 Resident, Department of Radiology, Shiraz University of Medical Sciences, Shiraz, Iran

4 Assistant Professor, Department of Otolaryngology, Shiraz University of Medical Sciences, Shiraz, Iran

5 Associate Professor, Department of Internal Medicine, Unit of Infection Disease, Healthy Policy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

6 Specialist in Community and Preventive Medicine, Researcher, Isfahan University of Medical Sciences, Isfahan

Abstract

Background: This study aimed to determine the causes of invasive fungal sinusitis in patients of Shiraz University hospitals, Iran.Methods: This cross sectional study was conducted during 18 months (from 21 March 2009 till 22 September 2010) in three Shiraz University Medical Hospitals Thirty six patients with sings of invasive fungal sinusitis were enrolled, and tissue samples were investigated for histopathology, culture and antifungal susceptibility test. The laboratory results with host factor and sinus computed tomography scan were evaluated for classification of patients as proven, probable and possible invasive fungal sinusitis.Findings: Thirty five patients have involved with at least one risk factor (immune compromised disease, diabetes mellitus, or use of immune suppressed drugs). Radiological findings of para sinus invasion or necrosis were present in 20 patients. By histopathology, 21 patients was considered as proven, from these 17 samples had positive growth. The culture etiology agents were 4 Candida, 8 Aspergillus, and 5 Mucor. All positive culture samples were “Match”ed with histopathology findings. Significant association were considered for radiologic finding and histopathology and culture (P < 0.05). From 8 patients with mucormycosis histopathology, 6 suffered from diabetes mellitus. None of the antifungal agents were effective on these three types of infections.  Conclusion: Imaging procedures can be used for diagnosis of infection in early stage of complication in high risk patients. 

Keywords


  1. Waitzman AA, Birt BD. Fungal sinusitis. J Otolaryngol 1994; 23(4): 244-9.
  2. DeShazo RD, Chapin K, Swain RE. Fungal sinusitis. N Engl J Med 1997; 337(4): 254-9.
  3. Mandell GL, Bennett JE, Dolin R. Principles and practice of infectious diseases. 7th ed. London: Churchill Livingstone/Elsevier; 2010. p. 3241-71.
  4. Martino R, Parody R, Fukuda T, Maertens J, Theunissen K, Ho A, et al. Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: A retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation
  5. Blood 2006; 108(9): 2928-36.
  6. Chua JL, Cullen JF. Fungal pan-sinusitis with severe visual loss in uncontrolled diabetes. Ann Acad Med Singapore 2008; 37(11): 964-7.
  7. Hadzri MH, Azarisman SM, Fauzi AR, Kahairi A. Invasive rhinocerebral mucormycosis with orbital extension in poorly- controlled diabetes mellitus. Singapore Med J 2009; 50(3): e107-e109.
  8. Miles AM, Barth RH. Aspergillus peritonitis: therapy, survival, and return to peritoneal dialysis. Am J Kidney Dis 1995; 26(1): 80-3.
  9. Bren A. Fungal peritonitis in patients on continuous ambulatory peritoneal dialysis. Eur J Clin Microbiol Infect Dis 1998; 17(12): 839-43.
  10. Ide L, De Laere E, Verlinde A, Surmont I. A case of Aspergillus fumigatus peritonitis in a patient undergoing continuous ambulatory peritoneal dialysis (CAPD): diagnostic and therapeutic challenges. J Clin Pathol 2005; 58(5): 559.
  11. Gillespie MB, O'Malley BW, Jr., Francis HW. An approach to fulminant invasive fungal rhinosinusitis in the immunocompromised host. Arch Otolaryngol Head Neck Surg 1998; 124(5): 520-6.
  12. Mardanei M, Abassei F, Agha Hasanei M, Hosseinei Shokouh SJ, Taleb Reza A, Agha Zedeh Sarhangei Pour K. Luqman Hakim Hospital reported four cases in 1388 Mvokoromaykoz Rinoserebral. Journal of the IR Iran Army University of Medical Sciences 2009; 7(2): 143-6.
  13. Ascioglu S, Rex JH, De Pauw B, Bennett JE, Bille J, Crokaert F, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34(1): 7-14.
  14. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46(12): 1813-21.
  15. DelGaudio JM, Swain RE, Jr., Kingdom TT, Muller S, Hudgins PA. Computed tomographic findings in patients with invasive fungal sinusitis. Arch Otolaryngol Head Neck Surg 2003; 129(2): 236-40.
  16. Taxy JB, El Zayaty S, Langerman A. Acute fungal sinusitis: natural history and the role of frozen section. Am J Clin Pathol 2009; 132(1): 86-93.
  17. Longworth DL. Update in infectious disease treatment. Cleve Clin J Med 2008; 75(8): 584-90.
  18. Pfaller MA, Yu WL. Antifungal susceptibility testing. New technology and clinical applications. Infect Dis Clin North Am 2001; 15(4): 1227-61.
  19. Patterson TF. Advances and challenges in management of invasive mycoses. Lancet 2005; 366(9490): 1013-25.
  20. Miladipour A, Ghanei E, Nasrollahi A, Moghaddasi H. Successful treatment of mucormycosis after kidney transplantation. Iran J Kidney Dis 2008; 2(3): 163-6.
  21. Jones BL, McLintock LA. Impact of diagnostic markers on early antifungal therapy. Curr Opin Infect Dis 2003; 16(6): 521-6.
  22. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347(6): 408-15.
  23. Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004; 39(6): 797-802.
  24. Meletiadis J, Te Dorsthorst DT, Verweij PE. The concentration-dependent nature of in vitro amphotericin B-itraconazole interaction against Aspergillus fumigatus: isobolographic and response surface analysis of complex pharmacodynamic interactions. Int J Antimicrob Agents 2006; 28(5): 439-49.
  25. Pitisuttithum P, Negroni R, Graybill JR, Bustamante B, Pappas P, Chapman S, et al. Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother 2005; 56(4): 745-55.